Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.45 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.45 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486687 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL10395152 | 0.90 | LMNA (0.41) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL11160234 | 0.81 | MAPT (0.66) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL10395173 | 0.80 | KMT2A (0.45) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL9126796 | 0.80 | LMNA (0.52) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL9126786 | 0.80 | LMNA (0.52) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL29279594 | 0.77 | LMNA (0.44) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL27368417 | 0.77 | LMNA (0.44) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL6523258 | 0.76 | PRKDC (0.49) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL6523261 | 0.76 | PRKDC (0.49) | MEN1KMT2AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951870-B2 | Coumarin derivatives with COMT inhibiting activity | ORION CORPORATION (FI) | 2005-10-04 | — | — | US | disclosed |
| US-20040110750-A9 | Coumarin derivatives with comt inhibiting activity | ORION CORPORATION (FI) | 2004-06-10 | — | — | US | disclosed |
| EP-1301503-B1 | COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY | ORION CORP (FI) | 2004-02-25 | — | — | EP | disclosed |
| US-20030186975-A1 | Coumarin derivatives with comt inhibiting activity | PYSTYNEN JARMO (FI) | 2003-10-02 | — | — | US | disclosed |
| EP-1301503-A1 | COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002002548-A1 | COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110750-A9 | Coumarin derivatives with comt inhibiting activity | COMT, CYP1A1, CYP2D6 | MEN1 3772/4885KMT2A 2987/4885MAPT 2880/4885 |
| US-20030186975-A1 | Coumarin derivatives with comt inhibiting activity | COMT, CYP1A1, CYP2D6 | MEN1 3772/4885KMT2A 2987/4885MAPT 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.